TNFRSF4 and neoplasm: Therapeutic targeting miR130b with OX40 agoniztic antibody and lipid nanoparticles (LNP)-miR130b antagomir significantly inhibited Th17 cells and miR130b-overexpressing tumor growth in vitro and in vivo, and could be candidates for immunotherapeutic strategies for treating OX40-deficient B-cell lymphoma.499